These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 14585859)

  • 1. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.
    Li J; Coulthard K; Milne R; Nation RL; Conway S; Peckham D; Etherington C; Turnidge J
    J Antimicrob Chemother; 2003 Dec; 52(6):987-92. PubMed ID: 14585859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.
    Li J; Milne RW; Nation RL; Turnidge JD; Smeaton TC; Coulthard K
    J Antimicrob Chemother; 2004 May; 53(5):837-40. PubMed ID: 15044428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses.
    Marchand S; Lamarche I; Gobin P; Couet W
    J Antimicrob Chemother; 2010 Aug; 65(8):1753-8. PubMed ID: 20507861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.
    Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB
    J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.
    Ratjen F; Rietschel E; Kasel D; Schwiertz R; Starke K; Beier H; van Koningsbruggen S; Grasemann H
    J Antimicrob Chemother; 2006 Feb; 57(2):306-11. PubMed ID: 16396919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study.
    Markou N; Fousteri M; Markantonis SL; Zidianakis B; Hroni D; Boutzouka E; Baltopoulos G
    J Antimicrob Chemother; 2012 Oct; 67(10):2459-62. PubMed ID: 22790220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.
    Westerman EM; De Boer AH; Le Brun PP; Touw DJ; Roldaan AC; Frijlink HW; Heijerman HG
    J Cyst Fibros; 2007 Jul; 6(4):284-92. PubMed ID: 17185047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.
    Yapa SWS; Li J; Patel K; Wilson JW; Dooley MJ; George J; Clark D; Poole S; Williams E; Porter CJ; Nation RL; McIntosh MP
    Antimicrob Agents Chemother; 2014 May; 58(5):2570-9. PubMed ID: 24550334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin®) to cystic fibrosis patients.
    Magréault S; Mankikian J; Marchand S; Diot P; Couet W; Flament T; Grégoire N
    J Cyst Fibros; 2020 May; 19(3):421-426. PubMed ID: 31501050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment on: pharmacokinetics of inhaled colistin in patients with cystic fibrosis.
    Li J; Nation RL
    J Antimicrob Chemother; 2006 Jul; 58(1):222-3; author reply 223. PubMed ID: 16641116
    [No Abstract]   [Full Text] [Related]  

  • 12. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
    Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
    Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of colistin in patients with cystic fibrosis.
    Reed MD; Stern RC; O'Riordan MA; Blumer JL
    J Clin Pharmacol; 2001 Jun; 41(6):645-54. PubMed ID: 11402633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.
    Mohamed AF; Cars O; Friberg LE
    J Antimicrob Chemother; 2014 May; 69(5):1350-61. PubMed ID: 24474432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
    Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
    Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates.
    Nakwan N; Usaha S; Chokephaibulkit K; Villani P; Regazzi M; Imberti R
    Pediatr Infect Dis J; 2016 Nov; 35(11):1211-1214. PubMed ID: 27276179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Güzel CB; Gerçeker AA
    Chemotherapy; 2008; 54(2):147-51. PubMed ID: 18322363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
    Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
    J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration.
    Karaiskos I; Friberg LE; Galani L; Ioannidis K; Katsouda E; Athanassa Z; Paskalis H; Giamarellou H
    Int J Antimicrob Agents; 2016 Sep; 48(3):337-41. PubMed ID: 27474468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.
    Cirillo I; Vaccaro N; Redman R; Black PL; Kearns GL
    J Clin Pharmacol; 2012 Nov; 52(11):1645-53. PubMed ID: 22174436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.